PFE · Q1 2026 Earnings
BullishPfizer
Reported May 5, 2026
30-second summary
Pfizer printed Q1 revenue of $14.45B (+2% reported YoY, +7% operational ex-COVID) and non-GAAP EPS of $0.75, reaffirming the full FY2026 framework of $59.5–$62.5B revenue and $2.80–$3.00 adjusted EPS. The strategic news is the post-2028 CAGR disclosure: following the Vyndamax patent settlement extending U.S. exclusivity to June 1, 2031, management has formally committed to a high-single-digit five-year revenue CAGR starting 2029 — a quantified post-cliff growth trajectory the company refused to underwrite a year ago. Launched and acquired products grew 22% to $3.1B, the obesity portfolio (Metsera) has a 2028 first-approval target, and the next-gen pneumococcal vaccine leapfrogged to a fifth-gen 35-serotype adult candidate entering clinical development this year.
Headline numbers
EPS
Q1 FY2026
$0.75
Revenue
Q1 FY2026
$14.45B
+2.0% YoY
Gross margin
Q1 FY2026
75.4%
Operating margin
Q1 FY2026
21.9%
Key financials
Q1 FY2026| Metric | Q1 FY2026 | YoY | Q4 FY2025 | QoQ |
|---|---|---|---|---|
| Revenue | $14.45B | +2.0% | $17.60B | -17.9% |
| EPS | $0.75 | — | $0.66 | +13.6% |
| Gross margin | 75.4% | — | 71.1% | +430bps |
| Operating margin | 21.9% | — | — | — |
Guidance
Company reaffirms all full-year 2026 guidance metrics including $59.5–$62.5B revenue and $2.80–$3.00 non-GAAP EPS; Q1 FY2026 reported $14.45B revenue (+2% YoY) and $0.75 non-GAAP EPS.
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
Reaffirmed unchanged this quarter: Revenue ($59.5 to $62.5 billion), Adjusted Diluted EPS ($2.80 to $3.00), Adjusted SI&A Expenses ($12.5 to $13.5 billion), Adjusted R&D Expenses ($10.5 to $11.5 billion), Effective Tax Rate on Adjusted Income (Approximately 15.0%)
Segment KPIs
Q1 FY2026| Segment | Q1 FY2026 | YoY |
|---|---|---|
| Primary Care | $5.542B | -6.0% |
| Oncology | $3.826B | +7.0% |
| Specialty Care | $2.939B | +8.0% |
| Hospital and Biosimilars | $1.854B | +10.0% |
Other KPIs
Q1 FY2026| Segment | Q1 FY2026 | YoY |
|---|---|---|
| United States | $8.731B | +4.0% |
| International | $5.719B | -1.0% |
| Operational Revenue Growth (excluding COVID products) | 7% | — |
| Padcev Operational Growth | 39% | — |
| Eliquis Operational Growth | 8% | — |
| Oncology Biosimilars Operational Growth | 52% | — |
| Nurtec ODT/Vydura Operational Growth | 41% | — |
| R&D Expenses | $2.49 billion | — |
| SG&A Expenses (Adjusted) | $2.92 billion | — |
| Adjusted Effective Tax Rate | 16.9% | — |
Management tone
Narrative arc: Q2 LOE bridge confidence → Q3 cost program as offense → Q4 catalytic-year pipeline pivot with EPS step-down → Q1 post-2028 growth trajectory quantified.
The post-2028 growth narrative moved from refused-to-quantify to a hard CAGR commitment. Three quarters ago management was selling cost-out as the structural margin lever and refused to underwrite a post-LOE growth rate; two quarters ago it shifted to "industry-leading growth at the end of the decade" without numbers; this quarter Denton said "Following the Vyndamax settlement, we now have a clear line of sight to a high single-digit five-year revenue CAGR post-2028." Pairing the Vyndamax patent extension to June 1, 2031 (a $6B+ cash-flow event) with a formal CAGR target is the most concrete forward financial framing Pfizer has put on the table this cycle. The shift signals management believes the LOE-offset math now closes from a known top-line floor rather than a hope-and-pipeline bridge.
Obesity moved from "high-priority M&A theme" to "10 phase three studies and a 2028 approval target." Two quarters ago obesity was framed as breaking science and an M&A combat zone (Metsera vs. Novo); this quarter the discussion is execution-level: "We intend to advance 10 phase three studies this year, and we are targeting a first approval in 2028 from a portfolio that includes ultra-long-acting peptides with the potential, if successful, developed and approved for competitive efficacy and tolerability with a differentiated monthly maintenance dosing schedule." The shift signals the Metsera capital deployment has been internalized into operating plans — the obesity opportunity is no longer being sold as optionality but as a 2028 P&L event.
Pneumococcal strategy went from "slipped a year" to "leapfrog to fifth-generation 35-serotype adult candidate." Two quarters ago the next-gen PCV adult 25 program slipped a year with explicit FDA-alignment dependency. This quarter management said "We have decided to advance directly to our fifth generation adult vaccine candidate. And today, I am proud to share for the first time that it includes coverage for 35 serotypes…we expect to enter clinical development this year." That's an unusually offensive posture in a franchise (Prevnar) where Merck has been closing — Pfizer is choosing to skip a generation rather than incrementally defend.
Oncology rhetoric shifted from integration-risk language to "transformed organization." Two quarters ago the post-Seagen narrative was still focused on PADCEV economics and the $42B price-tag math; this quarter Bourla said "we have transformed our oncology organization, unifying our team, expanding our commercial portfolio, and advancing a leading ADC platform" with 20% YoY operational revenue growth for the recently-launched-and-acquired oncology products. The integration is no longer a risk in the narrative — it's been promoted to a core growth engine.
COVID moved from "swing factor for the FY guide" (Q2) to "substantially de-risked" (Q3) to "headwind requiring exclusion" (Q1). Management is now framing the ex-COVID 7% growth as the operating signal and treating Paxlovid as a residual drag: "sustained low disease levels of COVID will likely continue to weigh on Paxlovid utilization over the next several months." The shift completes the journey from COVID-as-asset to COVID-as-noise.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Asad Hader · Goldman Sachs
How will Pfizer bridge the gap from $17 billion (now $14-15 billion post-Finda) of LOEs by 2030 to achieve high single-digit five-year revenue CAGR starting in 2029, and what are the embedded assumptions around base business (COVID, oncology) and pipeline contributions?
Management emphasized the $6 billion+ Finda LOE delay provides significant cash flow and EPS opportunity. The high single-digit CAGR assumes current portfolio decline through LOEs offset by heavily risk-adjusted pipeline assets (multiple redoubts rather than binary events) plus new/acquired products growing 22% and reaching ~$12 billion annually. New and acquired products growing 22% YoY, already at $3.1B in Q1.
Carrie Holford · Barenburg
What are vaccination rate expectations for COVID in US and international regions in 2025-2026, and how does the recent Belgian court decision impact European contract revenues and ex-US sales trajectory?
Management noted COVID vaccination rates in Europe stable vs 2024 (France ~25%, Spain ~35% adult rates), with governments committed to continued investment. Q1 decline in COVID revenue driven by UK contract completion (no longer in 2026 contract), not declining vaccination rates. Belgian court judgment being implemented with Poland and Romania; no specific details on revenue impact provided, but company working with governments on execution.
Louise Chin · Scotiabank
Which key products will drive reacceleration of growth in 2029 and beyond, and what was learned from the recent GLP-1 (ezetimibe) launch in China regarding international obesity opportunity?
Management identified growth drivers for 2029+: vaccines (pneumococcal, RSV) with large pediatric and adult populations; obesity assets (Danuglipron) as major growth catalyst entering developed markets as cash/direct-pay category; oncology (slower reimbursement timeline); existing franchises (Paxlovid, Prevnar with Lyme 303/304 upside; NerdTech CGRP with 40% conversion headroom; Vyndaxel with extended exclusivity). China ezetimibe launch week 1, but obesity prevalence in China is ~15% (one of largest markets globally), supporting collaboration with Cywin Bioscience; GLP-1 profile (15.1% weight loss at 48 weeks) competitive with best-in-class.
Uma Rafa · Evercore ISI
What is the likelihood of transformative M&A in near-to-medium term that could impact dividend, and how is management thinking about tenure and dividend integrity?
Management stated not focused on mega-mergers currently; 2026-2027 is about AI transformation of the organization requiring no mega-deal disruption. Remains 'open to everything' for M&A that creates shareholder value but it's 'not very high on our list.' CEO Albert Bourla indicated he plans to continue tenure, proud of COVID achievements, aims to replicate success with cancer, obesity, and vaccines.
Evan Zekerman · BMO Capital Markets
With clarity on Vyndaxel and post-2028 CAGR guidance, what additional catalysts or conditions are needed before Pfizer resumes share repurchases, particularly at current valuation levels?
Management indicated current capital allocation focus is on R&D investment and BD to drive long-term value. Court case clarity provides confidence in cash flow trajectory, making share repurchase consideration more likely going forward. Share buyback 'lever will come back into greater consideration' but timing dependent on balancing against R&D and BD priorities.
Answers to last quarter's watch list
What to watch into next quarter
Whether the FY revenue guide gets raised at Q2 once the ex-COVID 7% trajectory has two clean prints. If H1 ex-COVID operational growth holds at 7% and launched-and-acquired products stay at 22% YoY, the midpoint of $61.0B starts to look conservative — watch for a low-end bring-up rather than a full raise.
Adjusted tax rate convergence to the ~15.0% FY guide. Q1 printed 16.9%; the FY guide implies H2 needs to run ~14% or lower. A second quarter above 15% would put the EPS midpoint of $2.90 at risk via the tax line alone.
Buyback restart trigger. Denton flagged the buyback lever as "coming back into greater consideration" — watch for a specific announcement at the Q2 print, given the Vyndamax patent extension has materially de-risked the multi-year cash-flow picture.
MFN/TrumpRx quantification. Still unsized inside FY2026 guidance. A discrete dollar disclosure or guide adjustment would be the cleanest forward signal — silence means the impact is either modest or being absorbed by cost program over-delivery.
Pneumococcal fifth-generation 35-serotype IND start. Management committed to entering clinical development "this year" — watch for a specific trial-start disclosure and any FDA-alignment commentary, especially given the prior generation's 2025 slip.
Obesity portfolio progress against the 10 phase three studies / 2028 first approval framework. The 2028 approval target is the load-bearing assumption for the high-single-digit post-2028 CAGR commitment. Watch for cumulative trial-start count at Q2 and Q3.
Sources
- Pfizer Q1 2026 Earnings Press Release (SEC EX-99): https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-3292026xex99.htm
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.